Compare SYPR & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYPR | HOWL |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 46.7M |
| IPO Year | 1996 | 2021 |
| Metric | SYPR | HOWL |
|---|---|---|
| Price | $1.41 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 55.1K | ★ 303.6K |
| Earning Date | 12-01-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,294,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $0.27 |
| 52 Week High | $4.74 | $1.20 |
| Indicator | SYPR | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 50.10 |
| Support Level | N/A | $0.93 |
| Resistance Level | $1.91 | $1.12 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 91.54 | 29.93 |
Sypris Solutions Inc provides products and engineering, design, and manufacturing services for a variety of critical infrastructure sectors, including energy, space, communications, defense, transport, chemical, and water. The company operates in two segments, Sypris Technologies and Sypris Electronics. Sypris Technologies segment includes the sale of forged, machined, welded and heat-treated steel components for heavy commercial vehicle and high-pressure energy pipeline applications, whereas the Sypris Electronics segment includes revenue from circuit card and box build manufacturing, high reliability manufacturing and systems assembly and integration, for aerospace and defense, communications and space applications. The majority of revenue is derived from the Sypris Electronics segment.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.